ALK and anaplastic large cell lymphoma: While the role of ASCT is still debatable, our current practice is to offer ASCT in transplant-eligible patients (1) with non-ALCL treated with BV + CHP or CHO(E)P, (2) with high-risk IPI ALK-negative ALCL, or (3) who are older and who have ALK-positive ALCL, based on outcome data according to prognostic scoring and genetic subtype (Figure 1) [77,78].